Ariad Pharmaceuticals Stock Shines on Iclusig Opinion (NASDAQ:ARIA)

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)

As stock analyst speculate on Walmart signaling international intent, let’s check out another Company that has major European intent. It has to do a lot with a affirmation opinion by the European Medicines Agency on the continuing accessibility of Iclusig in Patients with Leukaemias. Ariad Pharmaceuticals ticker symbol ARIA, specializes in integrated global oncology company specializing in areas of cancer with innovative breakthrough medicines. The Company (www.ariad.com) launched Up +36.77% Up 1.39 generating over 63.2 million shares in play Monday November 25, 2013 2:14PM EST. If your wondering why, here is what we know about the stock.

Iclusig is used to treat a type of blood cancer called chronic myeloid leukemia, or Philadelphia chromosome positive acute lymphoblastic leukemia. The global market concerning cancer therapies is estimated to reach around $110.6 billion by the end of 2013.  Iclusig interferes with process of some cancer cells increasing in physical size. As November continues to shine on this global healthcare firm giant, investors just can’t act like the stock isn’t up +140.46% when compared with the 52 week low.

****

Orexigen Therapeutics, Inc. (NASDAQ:OREX)

As analyst expect the global anti obesity therapeutic market to scale over $1.8 billion by 2018, let’s take a look at Orexigen Therapeutics ticker symbol OREX. Orexigen Therapeutics specializes as a bio pharmaceutical company targeting the treatment of obesity. The Company (www.orexigen.com) spurted Up +10.92% Up 0.62 generating over 13.5 million shares in play in today’s financial markets Monday November 25, 2013 2:50PM EST.  So what’s pushing the stock Up you ask? The answer is Contrave® Light Study results.

The Contrave® Light Study is a double-blind, placebo-controlled cardiovascular outcomes trial for the purpose of ruling out excess cardiovascular risk in overweight and obese patients receiving Contrave®.  The ace with a kicker is that the interim analysis of the Light Study distinctly achieved the goal set by the United States Food and Drug Administration. The stock is Up +38.76% concerning the Company’s 52 week low. In layman’s terms you could say that Orexigen Therapeutics stock could potentially see the light. 

Remember: Always do your homework and consult your own financial professional.

Read Full Disclaimer at http://bestotc.com/disclaimer/